New tuberculosis research presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver offers important updates on TB prevention and treatment for people living with HIV. TAG summarizes key findings on short-course preventive therapy, treatment dosing strategies, and emerging long-acting technologies. Read TAG’s analysis.
TAGLine 2025 documents a year of action as Treatment Action Group defended science, confronted attacks on public health, and fought to protect communities impacted by HIV, TB, and HCV.
From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first of its kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines.
This Hepatitis C virus (HCV) storyboard describes the experience of Sibusiso Dlamini in Tsawne, South Africa. Sibusiso is a young man who began using substances for leisure in high school, and later in life switched to injecting substances for a stronger high.
TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.
Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.
TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.